OraSure Technologies, Inc. (OSUR)

US — Healthcare Sector
Peers: AKYA  ATRC  ATRI  ICUI  HAE  MMSI  ANGO  ATR  NVST    HOLX  COO  NSTG  KRMD 

Automate Your Wheel Strategy on OSUR

With Tiblio's Option Bot, you can configure your own wheel strategy including OSUR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol OSUR
  • Rev/Share 1.2419
  • Book/Share 5.2931
  • PB 0.5309
  • Debt/Equity 0.0358
  • CurrentRatio 12.3429
  • ROIC -0.0902

 

  • MktCap 210188281.0
  • FreeCF/Share -0.0232
  • PFCF -121.0762
  • PE -6.5833
  • Debt/Assets 0.031
  • DivYield 0
  • ROE -0.0771

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Orasure Technologies: Multiple Shots To Deliver Value
OSUR
Published: May 28, 2025 by: Seeking Alpha
Sentiment: Positive

OSUR remains deeply undervalued, trading below liquidation value, with a robust, cash-rich, debt-free balance sheet providing downside protection. Key value drivers include a 20% share buyback, potential building sale, and new product launches both in-house and via partnerships. Operational improvements—cost reductions, automation, and product diversification—should support gross margins and future growth.

Read More
image for news Orasure Technologies: Multiple Shots To Deliver Value
OraSure Technologies, Inc. (OSUR) Q1 2025 Earnings Call Transcript
OSUR
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral

OraSure Technologies, Inc. (NASDAQ:OSUR ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Jason Plagman - VP of Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Andrew Cooper - Raymond James Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies, Inc. 2025 First Quarter Earnings Conference Call.

Read More
image for news OraSure Technologies, Inc. (OSUR) Q1 2025 Earnings Call Transcript
OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates
OSUR
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative

OraSure Technologies (OSUR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.04 per share a year ago.

Read More
image for news OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates
OraSure Technologies: Historically Cheap
OSUR
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Positive

OraSure Technologies shares have dipped below $3 since my last writing, making shares even cheaper. Recent developments at the company include the acquisition of Sherlock Biosciences and the announcement of a $40 million share repurchase program. OSUR is enhancing business efficiency through cost cuts and aims to expand gross margins to 50% by year-end 2025, mitigating acquisition-related cash burn.

Read More
image for news OraSure Technologies: Historically Cheap
OraSure Announces $40 Million Stock Repurchase Program
OSUR
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to $40 million of its common stock over the next twenty-four months, which will be funded from cash on hand.

Read More
image for news OraSure Announces $40 Million Stock Repurchase Program
OraSure Technologies, Inc. (OSUR) Q4 2024 Earnings Call Transcript
OSUR
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral

OraSure Technologies, Inc. (NASDAQ:OSUR ) Q4 2024 Results Conference Call February 25, 2025 5:00 PM ET Company Participants Jason Plagman - VP of Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Casey Woodring - JPMorgan Andrew Cooper - Raymond James Operator Welcome to the OraSure Technologies, Inc. 2024 Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

Read More
image for news OraSure Technologies, Inc. (OSUR) Q4 2024 Earnings Call Transcript
OraSure Technologies (OSUR) Reports Q4 Loss, Tops Revenue Estimates
OSUR
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Negative

OraSure Technologies (OSUR) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.22 per share a year ago.

Read More
image for news OraSure Technologies (OSUR) Reports Q4 Loss, Tops Revenue Estimates
OraSure to Announce Fourth Quarter 2024 Financial Results and Host Earnings Call on February 25th
OSUR
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

BETHLEHEM, Pa., Feb. 14, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering fourth quarter 2024 financial results and certain business developments for 5 p.m. ET on February 25, 2025.

Read More
image for news OraSure to Announce Fourth Quarter 2024 Financial Results and Host Earnings Call on February 25th

About OraSure Technologies, Inc. (OSUR)

  • IPO Date 1986-11-17
  • Website https://www.orasure.com
  • Industry Medical - Instruments & Supplies
  • CEO Ms. Carrie Eglinton Manner
  • Employees 501

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.